Sunesis Pharmaceuticals (SNSS) Misses Q1 EPS by 12c

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q1 EPS of ($0.30), $0.12 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $0 versus the consensus estimate of $90 thousand.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c
• Dare Bioscience (DARE) Tops Q2 EPS by 11c